Breast cancer after hormone replacement therapy--does prognosis differ in perimenopausal and postmenopausal women?

Baumgärtner, AK; Häusler, A; Seifert-Klauss, V; Schuster, T; Schwarz-Boeger, U; Kiechle, M

doi:10.1016/j.breast.2011.04.010

2011

Back
Back to start of result list
Permanent link for displayed object

Title:: Breast cancer after hormone replacement therapy--does prognosis differ in perimenopausal and postmenopausal women?
Document type:: Journal Article
Author(s):: Baumgärtner, AK; Häusler, A; Seifert-Klauss, V; Schuster, T; Schwarz-Boeger, U; Kiechle, M
Abstract:: Hormone replacement therapy (HRT) has been associated with higher incidence of breast cancer in postmenopausal women, but it is unclear if breast cancers developing after HRT use have different prognosis. 1053 women with hormone receptor positive non-metastasized breast cancer were analyzed in a retrospective trial, stratifying by HRT use before diagnosis. Postmenopausal HRT users had significantly more early tumor stages (p<0.001). HRT in postmenopausal patients was associated with longer time to progression (TTP) (HR 0.81, 95%CI 0.55-1.19, p=0.28) and overall survival (OS) (HR 0.68, 95%CI 0.45-1.02, p=0.059). Perimenopausal HRT users showed shorter TTP and OS (HR 1.99, 95%CI 0.57-6.91, p=0.28 and HR 4.59, 95%CI 0.91-23.25, p=0.06 respectively). Higher BMI was significantly associated with poorer prognosis in perimenopausal women only (TTP: HR=1.16; OS: HR=1.31). In this retrospective analysis postmenopausal HRT users seemed to have a better breast cancer prognosis. For perimenopausal HRT users however, a trend towards worse prognosis was found.
Journal title abbreviation:: Breast
Year:: 2011
Journal volume:: 20
Journal issue:: 5
Pages contribution:: 448-54
Language:: eng
Fulltext / DOI:: doi:10.1016/j.breast.2011.04.010
Pubmed ID:: http://view.ncbi.nlm.nih.gov/pubmed/21652211
Print-ISSN:: 0960-9776
TUM Institution:: Frauenklinik und Poliklinik; Institut für Medizinische Statistik und Epidemiologie
BibTeX